Considering the apparently non-overlapping toxicity and the proved individual efficacy of GEM , oxaliplatin ( L-OHP ) , and capecitabine ( CAP ) , this randomized phase II study compared the activity and safety of the combination GEM , L-OHP , and CAP ( GEMOXEL ) versus GEM alone , in patients with metastatic pancreatic cancer .